PureTech Health
500 Boylston Street
Suite 1600
Boston
Massachusetts
02116
United States
Tel: 617-482-2333
Fax: 617-482-3337
Website: http://www.puretechventures.com/
Email: info@puretechventures.com
168 articles about PureTech Health
-
PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate
7/14/2022
PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate.
-
Aviv Clinics reported data from a study that suggests hyperbaric oxygen therapy may alleviate long COVID symptoms, particularly those associated with cognition.
-
Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.
-
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)
6/30/2022
IPF study will evaluate efficacy of two doses of LYT-100, one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability and efficacy vs. pirfenidone.
-
COVID-19 Research: Paxlovid Disappoints in Standard-Risk Setting, Nasal Spray Offers New Hope
6/15/2022
Biopharma has been stepping up research and drug development against COVID-19 -though results haven't always been encouraging. Here are the latest stories from this space: -
PureTech to Present at the Jefferies Healthcare Conference
6/1/2022
PureTech Health plc today announced that Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Legal & Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022, at 9:30am EDT.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
PureTech to Present at the UBS Global Healthcare Conference
5/17/2022
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2022, at 10:45am EDT.
-
PureTech Announces Share Buyback Program of up to $50 Million
5/5/2022
PureTech Health plc announces that its Board of Directors has approved a share buyback program in respect of its ordinary shares of one pence each up to a maximum consideration of $50 million.
-
PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)
4/12/2022
PureTech Health plc announced the publication of preclinical proof-of-concept demonstrating that PureTech’s Glyph platform can enhance the oral bioavailability of buprenorphine, a clinically-validated opioid replacement therapy, further expanding the range of clinically-validated drug classes shown to be amenable to the Glyph technology.
-
PureTech Health: Notice of Results
4/7/2022
PureTech Health plc plans to publish its annual report and financial results on Tuesday, April 26, 2022 at 2:00 AM EDT / 7:00 AM BST.
-
PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning
2/17/2022
PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx ® Activates Systems in Brain Key to Attentional Functioning.
-
PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
2/15/2022
PureTech Health plc announced that Social Capital Suvretta Holdings Corp. I has filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4, which contains a preliminary proxy statement/prospectus, in connection with the previously announced proposed business combination with Akili.
-
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
1/26/2022
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
-
PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference
1/7/2022
PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference.
-
PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone
1/6/2022
PureTech Health plc announced results from a randomized, double-blind crossover study in healthy older adults demonstrating that approximately 50% fewer subjects treated with PureTech’s LYT-100 experienced gastrointestinal -related adverse events compared to subjects treated with pirfenidone.
-
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
1/5/2022
Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing.
-
PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions
12/8/2021
PureTech Health plc today announced the presentation of preclinical proof-of-concept data at the 60th American College of Neuropsychopharmacology (ACNP) Annual Meeting.
-
PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
12/7/2021
PureTech Health plc announced today the initiation of a clinical study of LYT-300 (oral allopregnanolone), PureTech’s wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others.
-
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
12/1/2021
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity ® , Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer.